EP3600393A4 - COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS - Google Patents

COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS Download PDF

Info

Publication number
EP3600393A4
EP3600393A4 EP18771103.1A EP18771103A EP3600393A4 EP 3600393 A4 EP3600393 A4 EP 3600393A4 EP 18771103 A EP18771103 A EP 18771103A EP 3600393 A4 EP3600393 A4 EP 3600393A4
Authority
EP
European Patent Office
Prior art keywords
solid
treatment
combination therapy
hematological cancers
hematological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18771103.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3600393A1 (en
Inventor
Pamela T. Manning
Robyn PURO
Juan C. Almagro
Robert W. KARR
Benjamin J. CAPOCCIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Oncology Inc
Original Assignee
Arch Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/871,802 external-priority patent/US20180142019A1/en
Application filed by Arch Oncology Inc filed Critical Arch Oncology Inc
Publication of EP3600393A1 publication Critical patent/EP3600393A1/en
Publication of EP3600393A4 publication Critical patent/EP3600393A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
EP18771103.1A 2017-03-22 2018-03-22 COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS Withdrawn EP3600393A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762475032P 2017-03-22 2017-03-22
US201762475036P 2017-03-22 2017-03-22
US15/871,802 US20180142019A1 (en) 2016-10-21 2018-01-15 Therapeutic cd47 antibodies
PCT/US2018/023860 WO2018175790A1 (en) 2017-03-22 2018-03-22 Combination therapy for the treatment of solid and hematological cancers

Publications (2)

Publication Number Publication Date
EP3600393A1 EP3600393A1 (en) 2020-02-05
EP3600393A4 true EP3600393A4 (en) 2020-12-23

Family

ID=63585757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18771103.1A Withdrawn EP3600393A4 (en) 2017-03-22 2018-03-22 COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS

Country Status (7)

Country Link
EP (1) EP3600393A4 (enExample)
JP (1) JP7170331B2 (enExample)
CN (1) CN111148535A (enExample)
AU (1) AU2018240377A1 (enExample)
CA (1) CA3057139A1 (enExample)
SG (1) SG11201908602UA (enExample)
WO (1) WO2018175790A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
CN113166257B (zh) * 2018-12-03 2023-05-30 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
JP2022532249A (ja) * 2019-05-16 2022-07-13 アーチ オンコロジー，インコーポレイテッド インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2021080920A2 (en) * 2019-10-23 2021-04-29 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CN120040592A (zh) * 2020-07-31 2025-05-27 百奥泰生物制药股份有限公司 Cd47抗体及其应用
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040073013A1 (en) * 1999-03-10 2004-04-15 Naoshi Fukushima Polypeptide inducing apoptosis
WO2014123580A1 (en) * 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
PT2242773T (pt) * 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
MX2012008383A (es) * 2010-01-21 2012-11-23 Immunogen Inc Composiciones y metodos para el tratamiento de cancer de ovario.
ME03512B (me) * 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
EP2744830A4 (en) * 2012-06-21 2015-06-17 Compugen Ltd LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
US9221908B2 (en) * 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040073013A1 (en) * 1999-03-10 2004-04-15 Naoshi Fukushima Polypeptide inducing apoptosis
WO2014123580A1 (en) * 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANA-CAROLINA MARTINEZ-TORRES ET AL: "CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLC[gamma]1 Activation: Evidence from Mice and Humans", PLOS MEDICINE, vol. 12, no. 3, 3 March 2015 (2015-03-03), pages e1001796, XP055318218, DOI: 10.1371/journal.pmed.1001796 *
JESSICA LO ET AL: "Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma", LIVER INTERNATIONAL, vol. 36, no. 5, 1 May 2016 (2016-05-01), GB, pages 737 - 745, XP055505901, ISSN: 1478-3223, DOI: 10.1111/liv.12963 *
KATHAWALA: "Abstract 4001: The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy | Cancer Research", AACR 107TH ANNUAL MEETING 2016, vol. 76, 15 July 2016 (2016-07-15), XP055506116, DOI: 10.1158/1538-7445.AM2016-4001 *
PARTHA MANNA ET AL: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-1708 *
PER-ARNE OLDENBORG: "CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease", ISRN HEMATOLOGY, 1 January 2013 (2013-01-01), pages 1 - 19, XP055663144, DOI: 10.1155/2013/614619 *
ROBERT W KARR: "Experimental data on anti-CD47 antibodies", OPPOSITION PROCEEDINGS RELATING TO EUROPEAN PATENT EP2242512, 20 January 2017 (2017-01-20), pages 1 - 11, XP055692350, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP09701993&lng=en&tab=doclist> [retrieved on 20200506] *
See also references of WO2018175790A1 *
XIAOJUAN LIU ET AL: "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors", NATURE MEDICINE, vol. 21, no. 10, 31 October 2015 (2015-10-31), New York, pages 1209 - 1215, XP055478072, ISSN: 1078-8956, DOI: 10.1038/nm.3931 *

Also Published As

Publication number Publication date
JP7170331B2 (ja) 2022-11-14
CN111148535A (zh) 2020-05-12
EP3600393A1 (en) 2020-02-05
SG11201908602UA (en) 2019-10-30
JP2020511481A (ja) 2020-04-16
CA3057139A1 (en) 2018-09-27
AU2018240377A1 (en) 2019-10-31
WO2018175790A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
IL267795A (en) Combined treatment for cancer
EP3630089A4 (en) PROCEDURE FOR CANCER THERAPY
AU2017260425B2 (en) Combination therapy for cancer treatment
EP3307240A4 (en) Combination therapy for the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
SMT202000152T1 (it) Derivati di diidroimidazopirazinone utili nel trattamento di cancro
EP3548028A4 (en) CANCER TREATMENT
EP4048406A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS
EP3860610A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
EP3548007A4 (en) METHOD OF TREATMENT OF CANCER
EP3897649A4 (en) COMBINATION THERAPY FOR SOLID TUMOR
IL266993A (en) Combined therapy for cancer treatment
SI3630112T1 (sl) Kombinacija regorafeniba in nivolumaba za zdravljenje raka
SG11202000724XA (en) Methods and compositions for the treatment of cancer
EP3478293A4 (en) MAINTENANCE THERAPY FOR CANCER TREATMENT
IL280262A (en) Compositions and methods for treating cancer
IL253642A0 (en) Combined treatment for cancer
AU2017902291A0 (en) Antibody-Drug-Conjugates And Uses Thereof For The Treatment of Cancer
AU2018902173A0 (en) Antibody-Drug-Conjugates And Uses Thereof For The Treatment Of Cancer
HK40029034A (en) Methods and compositions for the treatment of cancer
AU2019902149A0 (en) Antibody-Drug-Conjugates And Uses Thereof For The Treatment Of Cancer
HK40009465A (en) Combination therapy for the treatment of cancer
HK40061708A (en) Combination therapy for the treatment of cancer
HK40060019A (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039000000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20201125

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20201119BHEP

Ipc: A61K 35/28 20150101ALI20201119BHEP

Ipc: C07K 16/28 20060101AFI20201119BHEP

Ipc: C12N 5/0786 20100101ALI20201119BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231116